-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, in the context of the continuous growth of the scale of global biomedicine, the efficiency of medical research and development has been declining, and the cost and time of research and development of a new drug have increased exponentially
.
In this context, AI, which is good at data processing and analysis, has gradually attracted great attention in the industry
.
And as pharmaceutical companies continue to taste the "sweetness" of AI pharmacy, this track has also begun to heat up, and more and more companies are accelerating their entry
.
For example, Roche and Genentech signed a broad cooperation agreement with Recursion, which uses artificial intelligence to drive drug discovery
.
It is reported that this cooperation transaction includes a huge advance payment of 150 million U.
S.
dollars.
The drug development will also allow the two parties to conduct up to 40 separate projects in the field of neurology and cancer in the next ten years.
Potential milestone payments of $300 million and royalties
.
Prior to this, Google’s parent company Alphabet also announced the establishment of a new company, Isomorphic Laboratories, an AI pharmaceutical company that will develop on the basis of the research on the London Artificial Intelligence Laboratory DeepMind’s successful prediction of protein structure, aiming to use the depth of intelligent AI The learning method is applied to drug discovery
.
From the above point of view, the current development of AI pharmaceuticals has been very hot
.
In fact, in China, in addition to local pharmaceutical companies, Internet technology giants including ByteDance, Tencent, Baidu, and Huawei have already begun to get involved in the AI pharmaceutical field, and capital is constantly increasing in related companies
.
According to statistics, in the first half of 2021, the total amount of funding for the AI pharmaceutical competition has exceeded 1 billion yuan
.
In the second half of the year, multiple financing news broke out in the AI pharmaceutical field
.
For example, on October 15, Xunbaihui, which focuses on the research and development of innovative tumor immune AI drugs, announced that it has completed a tens of millions of dollars in Series B financing led by IDG Capital.
The funds raised will be used to promote the clinical development of new target antibody and new drug projects, and Research and development of multiple drug pipelines related to tumor immune targets; On October 13th, Matrix Partners and Wuyuan Capital jointly led the investment in Woshi Technology’s Pre-A round, with a transaction amount of nearly 10 million U.
S.
dollars, etc.
.
It is worth mentioning that, as pharmaceutical companies continue to increase their weight in AI pharmacy, some companies have made substantial breakthroughs in the research and development of new drugs
.
For example, in January 2020, Exscientia, a British AI pharmaceutical startup, announced that it used AI-designed immuno-oncology molecule EXS21546 to enter human clinical trials
.
At present, Exscientia has reached cooperation with well-known pharmaceutical companies such as Bayer, Sanofi, and GlaxoSmithKline
.
However, it should be noted that, on the whole, most pharmaceutical companies are in the AI pharmaceutical field at this stage, and most of them are still in the early stage of drug research and development
.
In addition, most of the commercialization of domestic AI pharmaceutical companies is still seeking cooperation with large foreign pharmaceutical companies such as Johnson & Johnson, Merck, Pfizer, etc.
, to provide technical services for them, and they have not yet been able to take their own path
.
In this context, the industry expects that domestic and foreign AI pharmacies will experience a period of growth and ramp-up
.
However, with the continuous development of the AI pharmaceutical market, the future AI drug research and development will no longer be a conceptual technology in the biomedical industry, but will become a very core existence in the industry
.
.
In this context, AI, which is good at data processing and analysis, has gradually attracted great attention in the industry
.
And as pharmaceutical companies continue to taste the "sweetness" of AI pharmacy, this track has also begun to heat up, and more and more companies are accelerating their entry
.
For example, Roche and Genentech signed a broad cooperation agreement with Recursion, which uses artificial intelligence to drive drug discovery
.
It is reported that this cooperation transaction includes a huge advance payment of 150 million U.
S.
dollars.
The drug development will also allow the two parties to conduct up to 40 separate projects in the field of neurology and cancer in the next ten years.
Potential milestone payments of $300 million and royalties
.
Prior to this, Google’s parent company Alphabet also announced the establishment of a new company, Isomorphic Laboratories, an AI pharmaceutical company that will develop on the basis of the research on the London Artificial Intelligence Laboratory DeepMind’s successful prediction of protein structure, aiming to use the depth of intelligent AI The learning method is applied to drug discovery
.
From the above point of view, the current development of AI pharmaceuticals has been very hot
.
In fact, in China, in addition to local pharmaceutical companies, Internet technology giants including ByteDance, Tencent, Baidu, and Huawei have already begun to get involved in the AI pharmaceutical field, and capital is constantly increasing in related companies
.
According to statistics, in the first half of 2021, the total amount of funding for the AI pharmaceutical competition has exceeded 1 billion yuan
.
In the second half of the year, multiple financing news broke out in the AI pharmaceutical field
.
For example, on October 15, Xunbaihui, which focuses on the research and development of innovative tumor immune AI drugs, announced that it has completed a tens of millions of dollars in Series B financing led by IDG Capital.
The funds raised will be used to promote the clinical development of new target antibody and new drug projects, and Research and development of multiple drug pipelines related to tumor immune targets; On October 13th, Matrix Partners and Wuyuan Capital jointly led the investment in Woshi Technology’s Pre-A round, with a transaction amount of nearly 10 million U.
S.
dollars, etc.
.
It is worth mentioning that, as pharmaceutical companies continue to increase their weight in AI pharmacy, some companies have made substantial breakthroughs in the research and development of new drugs
.
For example, in January 2020, Exscientia, a British AI pharmaceutical startup, announced that it used AI-designed immuno-oncology molecule EXS21546 to enter human clinical trials
.
At present, Exscientia has reached cooperation with well-known pharmaceutical companies such as Bayer, Sanofi, and GlaxoSmithKline
.
However, it should be noted that, on the whole, most pharmaceutical companies are in the AI pharmaceutical field at this stage, and most of them are still in the early stage of drug research and development
.
In addition, most of the commercialization of domestic AI pharmaceutical companies is still seeking cooperation with large foreign pharmaceutical companies such as Johnson & Johnson, Merck, Pfizer, etc.
, to provide technical services for them, and they have not yet been able to take their own path
.
In this context, the industry expects that domestic and foreign AI pharmacies will experience a period of growth and ramp-up
.
However, with the continuous development of the AI pharmaceutical market, the future AI drug research and development will no longer be a conceptual technology in the biomedical industry, but will become a very core existence in the industry
.
